Investigating a new vaccine approach to enhance T-cell responses against HIV
Official title: Contributions of durable, high-avidity T-cell responses to protection achieved using the Opti-FliP vaccine regimen
Funded at University of California at Davis · NIH-11062311 · Data updated 2026-11-12
This study is looking at new ways to create vaccines that help your body build strong and lasting defenses against SHIV, which is similar to HIV, by boosting both T-cells and B-cells to improve your overall immune protection, and you might have the chance to participate in trials to see how well these new vaccines work.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | December 17, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $1,260,330 |
| NIH project number | 1P01AI181044-01A1 |
| Project ID | NIH-11062311 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals at high risk for HIV infection or those living with HIV who are seeking improved treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who have already achieved viral suppression with existing therapies may not benefit from this research.
What this research studies
This research focuses on developing innovative vaccine strategies to elicit strong and long-lasting T-cell responses that can protect against SHIV infection, a model for HIV. The study aims to combine these T-cell responses with B-cell vaccines to enhance overall immune protection. By using specific cytokines and targeting high-avidity T cells, the researchers hope to create a more effective immune response that can lead to better outcomes for individuals at risk of HIV. Patients may be involved in trials to assess the efficacy of these new vaccine regimens.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against HIV infection.
How similar studies have gone: While there have been challenges in previous HIV vaccine trials, this approach is innovative and aims to build on lessons learned from past studies, suggesting potential for success.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Hartigan-O'connor, Dennis J. — University of California at Davis
- Study coordinator: Hartigan-O'connor, Dennis J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.